Mirum Pharmaceuticals, Inc. 4

Mirum Pharmaceuticals CEO Christopher Peetz exercised 30,000 stock options at $2.936 and sold 30,000 common shares around $98–$99 per share in planned transactions, ending with 194,440 shares held directly.

On September 1, 2026, Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option to acquire 30,000 shares of common stock at an exercise price of $2.936 per share (approximately $88,080 in value), then sold a total of 30,000 shares in two open-market transactions under a Rule 10b5-1 plan: 8,312 shares at a weighted average price of $98.08 per share (about $815,000) and 21,688 shares at a weighted average price of $98.91 per share (about $2.14 million). These sales appear to be a classic cashless exercise-and-sell, converting option value into cash with no net change in directly held share count versus the immediate post-exercise position. After these transactions, Peetz directly owned 194,440 shares of Mirum common stock, plus an additional 187,500 shares held indirectly by The Peetz Family Trust, and the reported holdings include 131 shares acquired earlier via the issuer’s employee stock purchase plan.

Filing Facts

CIK

1759425

Ticker

MIRM

Form

4

Source Type

fda

Accession

0001614740-26-000013

Alert Tier

7